UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

NPJ breast cancer, 2023-11, Vol.9 (1), p.94-94, Article 94

2023

Volltextzugriff (PDF)

Long-term health-related burden of adult congenital heart diseases in Hong Kong

Journal of medical economics, 2019-08, Vol.22 (8), p.814-817

2019

Volltextzugriff (PDF)

The efficacy of femoral augmentation for hip fracture prevention using ceramic-based cements: A preliminary experimentally-driven finite element investigation

Frontiers in bioengineering and biotechnology, 2023-01, Vol.11, p.1079644-1079644

2023

Volltextzugriff (PDF)

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

Journal of clinical oncology, 2021-08, Vol.39 (24), p.2667-2675

2021

Volltextzugriff (PDF)

Evaluating femoral augmentation to prevent geriatric hip fracture: A scoping review of experimental methods

Journal of orthopaedic research, 2023-09, Vol.41 (9), p.1855-1862

2023

Volltextzugriff (PDF)

Cost-effectiveness of subcutaneous pertuzumab, trastuzumab, and hyaluronidase-zzxf for the treatment of high-risk HER2+ early breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18846-e18846

2021

Volltextzugriff (PDF)

How accurately do finite element models predict the fall impact response of ex vivo specimens augmented by prophylactic intramedullary nailing?

Journal of orthopaedic research, 2024-10

2024

Volltextzugriff (PDF)

Subject-specific ex vivo simulations for hip fracture risk assessment in sideways falls

Bone (New York, N.Y.), 2019-08, Vol.125, p.36-45

2019

Volltextzugriff (PDF)

Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e12648-e12648

2020

Volltextzugriff (PDF)

Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study

Breast cancer research and treatment, 2021-06, Vol.187 (3), p.903-913

2021

Volltextzugriff (PDF)

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach

Journal of Oncology Pharmacy Practice, 2021-07, Vol.27 (5), p.1214-1221

2021

Volltextzugriff (PDF)

Abstract PS10-20: Neoadjuvant (neoadj) and adjuvant (adj) treatment patterns in HER2-positive early breast cancer (EBC): Analysis of US real-world oncology data

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS10-20-PS10-20

2021

Volltextzugriff (PDF)

HOME CARDIAC SURVEILLANCE WITH ARTIFICIAL INTELLIGENCE DIGITAL PATIENT MONITORING DURING TREATMENT WITH PERTUZUMAB, TRASTUZUMAB AND HYALURONIDASE-ZZXF FOR HER2-POSITIVE BREAST CANCER (HARRIET): STUDY DESIGN AND RATIONALE

Journal of the American College of Cardiology, 2022-03, Vol.79 (9), p.2004

2022

Volltextzugriff (PDF)

Reply to J. Wei et al

Journal of clinical oncology, 2021-12, Vol.39 (36), p.4127-4128

2021

Volltextzugriff (PDF)

Prophylactic augmentation implants in the proximal femur for hip fracture prevention: An in silico investigation of simulated sideways fall impacts

Journal of the mechanical behavior of biomedical materials, 2022-02, Vol.126, p.104957-104957, Article 104957

2022

Volltextzugriff (PDF)

Effects of footwear and stride length on metatarsal strains and failure in running

Clinical biomechanics (Bristol), 2017-11, Vol.49, p.8-15

2017

Volltextzugriff (PDF)

Abstract P1-18-03: Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-18-03

2020

Volltextzugriff (PDF)

Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1515-1515

2022

Volltextzugriff (PDF)

Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States

Advances in therapy, 2023-09, Vol.40 (9), p.3857-3874

2023

Volltextzugriff (PDF)

Experimental validation of finite element predicted bone strain in the human metatarsal

Journal of biomechanics, 2017-07, Vol.60, p.22-29

2017

Volltextzugriff (PDF)

QOLP-02. PATIENT-REPORTED OUTCOMES FOLLOWING PERTUZUMAB PLUS HIGH-DOSE TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) AND CENTRAL NERVOUS SYSTEM (CNS) PROGRESSION POST-RADIOTHERAPY

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii174-ii175

2020

Volltextzugriff (PDF)

Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer

Advances in therapy, 2022-03, Vol.39 (3), p.1375-1392

2022

Volltextzugriff (PDF)

Correction to: Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer

Advances in therapy, 2022-07, Vol.39 (7), p.3423-3423

2022

Volltextzugriff (PDF)

An open-label, single-arm, phase II study of pertuzumab with high-dose trastuzumab for treatment of central nervous system (CNS) progression post-radiotherapy in patients (pts) with HER2-positive metastatic breast cancer (MBC): PATRICIA

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS633-TPS633

2016

Volltextzugriff (PDF)

Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2074-2074

2017

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Englisch
(101)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Long-term health-related burden of adult congenital heart diseases in Hong Kong

The efficacy of femoral augmentation for hip fracture prevention using ceramic-based cements: A preliminary experimentally-driven finite element investigation

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

Evaluating femoral augmentation to prevent geriatric hip fracture: A scoping review of experimental methods

Cost-effectiveness of subcutaneous pertuzumab, trastuzumab, and hyaluronidase-zzxf for the treatment of high-risk HER2+ early breast cancer

How accurately do finite element models predict the fall impact response of ex vivo specimens augmented by prophylactic intramedullary nailing?

Subject-specific ex vivo simulations for hip fracture risk assessment in sideways falls

Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence

Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach

Abstract PS10-20: Neoadjuvant (neoadj) and adjuvant (adj) treatment patterns in HER2-positive early breast cancer (EBC): Analysis of US real-world oncology data

HOME CARDIAC SURVEILLANCE WITH ARTIFICIAL INTELLIGENCE DIGITAL PATIENT MONITORING DURING TREATMENT WITH PERTUZUMAB, TRASTUZUMAB AND HYALURONIDASE-ZZXF FOR HER2-POSITIVE BREAST CANCER (HARRIET): STUDY DESIGN AND RATIONALE

Reply to J. Wei et al

Prophylactic augmentation implants in the proximal femur for hip fracture prevention: An in silico investigation of simulated sideways fall impacts

Effects of footwear and stride length on metatarsal strains and failure in running

Abstract P1-18-03: Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study

Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic

Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States

Experimental validation of finite element predicted bone strain in the human metatarsal

QOLP-02. PATIENT-REPORTED OUTCOMES FOLLOWING PERTUZUMAB PLUS HIGH-DOSE TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) AND CENTRAL NERVOUS SYSTEM (CNS) PROGRESSION POST-RADIOTHERAPY

Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer

Correction to: Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer

An open-label, single-arm, phase II study of pertuzumab with high-dose trastuzumab for treatment of central nervous system (CNS) progression post-radiotherapy in patients (pts) with HER2-positive metastatic breast cancer (MBC): PATRICIA

Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

Suchergebnisse filtern